Collaborative Care Cuts Fatigue, Pain in ESKD Hemodialysis Patients
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, June 23, 2023 -- A technology-assisted stepped collaborative care intervention can reduce fatigue and pain among patients with end-stage kidney disease (ESKD) undergoing hemodialysis, according to a study published online June 20 in JAMA Internal Medicine.
Manisha Jhamb, M.D., M.P.H., from the University of Pittsburgh School of Medicine, and colleagues compared the effectiveness of a stepped collaborative care intervention versus health education control for reducing fatigue, pain, and depression among ESKD patients undergoing long-term hemodialysis. The intervention group received 12 weekly sessions of cognitive behavioral therapy (CBT) delivered via telehealth and/or pharmacotherapy using a stepped approach in collaboration with dialysis and primary care teams, while the attention control group received six health education telehealth sessions (83 and 77 patients, respectively).
The researchers found that patients in the intervention group experienced statistically and clinically significant reductions in fatigue and pain severity at three months compared with controls in the intention-to-treat analyses (mean difference, 2.81 and −0.96, respectively). At six months, these effects were sustained (mean difference, 3.73 and −1.49, respectively). At three months, there was a statistically significant but small improvement seen in depression (mean difference, −1.73). Both groups had similar adverse events.
"Our results showed that among patients undergoing hemodialysis, a 12-week CBT-based stepped collaborative care intervention can offer clinically significant improvements in fatigue and pain," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...
Sleep Restriction Tied to Negative Cognitive Effects in Teens With Overweight, Obesity
WEDNESDAY, May 22, 2024 -- Adolescents with overweight or obesity may be more vulnerable to negative cognitive effects following sleep restriction, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.